Btw31 Oct 2020 20:47
ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded an Innovate UK grant as part of the “business-led innovation in response to global disruption” scheme, which was set up in light of the COVID-19 pandemic and will be utilised to develop novel sputum-based cytokine multiplex assays.
Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:
“A number of cytokines have been associated with COVID-19 infection so we anticipate an increased future need for extensive testing of these proteins in a range of biological fluids, both for monitoring people infected with the COVID-19 virus.